{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T09:27:03Z","timestamp":1792661223471,"version":"4.5.0"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2018,7,31]],"date-time":"2018-07-31T00:00:00Z","timestamp":1532995200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neural Transm"],"published-print":{"date-parts":[[2018,10]]},"DOI":"10.1007\/s00702-018-1911-3","type":"journal-article","created":{"date-parts":[[2018,7,31]],"date-time":"2018-07-31T08:23:26Z","timestamp":1533025406000},"page":"1481-1486","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":28,"title":["Antibody-induced failure of botulinum toxin therapy: re-start with low-antigenicity drugs offers a new treatment opportunity"],"prefix":"10.1007","volume":"125","author":[{"given":"Dirk","family":"Dressler","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lizhen","family":"Pan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fereshte","family":"Adib Saberi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,7,31]]},"reference":[{"key":"1911_CR1","first-page":"158","volume-title":"Handbook of botulinum toxin therapy","author":"R Benecke","year":"2003","unstructured":"Benecke R, Moore P, Dressler D, Naumann M (2003) Cervical and axial dystonia. In: Moore P, Naumann M (eds) Handbook of botulinum toxin therapy, 2nd\u00a0edn. Blackwell Science, Oxford, pp\u00a0158\u2013194","edition":"2"},{"key":"1911_CR2","doi-asserted-by":"publisher","first-page":"1949","DOI":"10.1212\/01.WNL.0000163767.99354.C3","volume":"64","author":"R Benecke","year":"2005","unstructured":"Benecke R, Jost WH, Kanovsky P, Ruzicka E, Comes G, Grafe S (2005) A new botulinum toxin type A free of complexing proteins for treatment of cervical dystonia. Neurology 64:1949\u20131951","journal-title":"Neurology"},{"key":"1911_CR3","doi-asserted-by":"publisher","first-page":"1494","DOI":"10.1212\/WNL.51.5.1494","volume":"51","author":"R Chen","year":"1998","unstructured":"Chen R, Karp BI, Hallett M (1998) Botulinum toxin type F for treatment of dystonia: long-term experience. Neurology 51:1494\u20131496","journal-title":"Neurology"},{"key":"1911_CR4","doi-asserted-by":"publisher","first-page":"921","DOI":"10.1111\/j.1526-4610.2010.01678.x","volume":"50","author":"DW Dodick","year":"2010","unstructured":"Dodick DW, Turkel CC, DeGryse RE, Aurora SK, Silberstein SD, Lipton RB, Diener HC, Brin MF, PREEMPT Chronic Migraine Study Group (2010) OnabotulinumtoxinA for treatment of chronic migraine: pooled results from the double-blind, randomized, placebo-controlled phases of the PREEMPT clinical program. Headache 50:921\u2013936","journal-title":"Headache"},{"key":"1911_CR5","doi-asserted-by":"publisher","first-page":"S92","DOI":"10.1002\/mds.20022","volume":"8","author":"D Dressler","year":"2004","unstructured":"Dressler D (2004) Clinical presentation and management of antibody-induced failure of botulinum toxin therapy. Mov Disord Suppl 8:S92\u2013S100","journal-title":"Mov Disord Suppl"},{"key":"1911_CR6","volume-title":"Antik\u00f6rperinduziertes Botulinum Toxin-Therapieversagen: Symptomatik, Abkl\u00e4rung, Behandlung","author":"D Dressler","year":"2005","unstructured":"Dressler D (2005) Antik\u00f6rperinduziertes Botulinum Toxin-Therapieversagen: Symptomatik, Abkl\u00e4rung, Behandlung. Habilitationsschrift, Universit\u00e4t Rostock, Rostock"},{"key":"1911_CR7","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1111\/j.1468-1331.2011.03559.x","volume":"19","author":"D Dressler","year":"2012","unstructured":"Dressler D (2012) Five-year experience with incobotulinumtoxinA (Xeomin\u00ae): the first botulinum toxin drug free of complexing proteins. Eur J Neurol 19:385\u2013389","journal-title":"Eur J Neurol"},{"key":"1911_CR8","doi-asserted-by":"publisher","first-page":"1761","DOI":"10.1080\/09638280701568296","volume":"29","author":"D Dressler","year":"2007","unstructured":"Dressler D, Benecke R (2007) Pharmacology of therapeutic botulinum toxin preparations. Disabil Rehabil 29:1761\u20131768","journal-title":"Disabil Rehabil"},{"key":"1911_CR9","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1002\/mds.1238","volume":"17","author":"D Dressler","year":"2002","unstructured":"Dressler D, Bigalke H (2002) Botulinum toxin antibody type A titres after cessation of botulinum toxin therapy. Mov Disord 17:170\u2013173","journal-title":"Mov Disord"},{"key":"1911_CR10","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1080\/14737175.2017.1262258","volume":"17","author":"D Dressler","year":"2017","unstructured":"Dressler D, Bigalke H (2017) Immunological aspects of botulinum toxin therapy. Expert Rev Neurother 17:487\u2013494","journal-title":"Expert Rev Neurother"},{"issue":"suppl 2","key":"1911_CR11","first-page":"51","volume":"15","author":"D Dressler","year":"2000","unstructured":"Dressler D, Dirnberger G (2000) Botulinum toxin therapy: risk factors for therapy failure. Mov Disord 15(suppl 2):51","journal-title":"Mov Disord"},{"key":"1911_CR12","doi-asserted-by":"publisher","first-page":"1279","DOI":"10.1002\/1531-8257(200011)15:6<1279::AID-MDS1040>3.0.CO;2-4","volume":"15","author":"D Dressler","year":"2000","unstructured":"Dressler D, Zettl U, Benecke R, Bigalke H (2000a) Can intravenous immunoglobulin improve antibody-mediated botulinum toxin therapy failure? Mov Disord 15:1279\u20131281","journal-title":"Mov Disord"},{"key":"1911_CR13","doi-asserted-by":"publisher","first-page":"973","DOI":"10.1002\/1531-8257(200009)15:5<973::AID-MDS1031>3.0.CO;2-X","volume":"15","author":"D Dressler","year":"2000","unstructured":"Dressler D, Dirnberger G, Bhatia KP, Irmer A, Quinn NP, Bigalke H, Marsden CD (2000b) Botulinum toxin antibody testing: comparison between the mouse protection assay and the mouse lethality assay. Mov Disord 15:973\u2013976","journal-title":"Mov Disord"},{"key":"1911_CR14","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1159\/000047963","volume":"47","author":"D Dressler","year":"2002","unstructured":"Dressler D, M\u00fcnchau A, Bhatia KP, Quinn NP, Bigalke H (2002) Antibody-induced botulinum toxin therapy failure: can it be overcome by increased botulinum toxin doses? Eur Neurol 47:118\u2013121","journal-title":"Eur Neurol"},{"key":"1911_CR15","doi-asserted-by":"publisher","first-page":"967","DOI":"10.1007\/s00415-003-1129-6","volume":"250","author":"D Dressler","year":"2003","unstructured":"Dressler D, Benecke R, Bigalke H (2003) Botulinum toxin type B (NeuroBloc\u00ae) in patients with botulinum toxin type A antibody-induced therapy failure. J Neurol 250:967\u2013969","journal-title":"J Neurol"},{"key":"1911_CR16","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1111\/ene.12330","volume":"21","author":"D Dressler","year":"2014","unstructured":"Dressler D, Kupsch A, Seitzinger A, Paus S (2014) The dystonia discomfort scale (DDS): a novel instrument to monitor the temporal profile of botulinum toxin therapy in cervical dystonia. Eur J Neurol 21:459\u2013462","journal-title":"Eur J Neurol"},{"key":"1911_CR17","unstructured":"Duane D, Monroe J (1999) Use of mycophenolate to prevent recurrence of botulinum toxin A antibodies in cervical dystonia. In: International conference 1999: basic and therapeutic aspects of botulinum and tetanus toxin, Orlando, November 16\u201318, 1999, p\u00a032"},{"key":"1911_CR18","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1007\/BF03033930","volume":"9","author":"R Eleopra","year":"2006","unstructured":"Eleopra R, Tugnoli V, Quatrale R, Rossetto O, Montecucco C, Dressler D (2006) Clinical use of non-A botulinum toxins: botulinum toxin type C and botulinum toxin type F. Neurotox Res 9:127\u2013131","journal-title":"Neurotox Res"},{"key":"1911_CR19","first-page":"325","volume":"4","author":"J Frevert","year":"2010","unstructured":"Frevert J, Dressler D (2010) Complexing proteins in botulinum toxin type A drugs: a help or a hindrance? Biologics 4:325\u2013332","journal-title":"Biologics"},{"key":"1911_CR20","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1006\/exnr.1997.6580","volume":"147","author":"H G\u00f6schel","year":"1997","unstructured":"G\u00f6schel H, Wohlfarth K, Frevert J, Dengler R, Bigalke H (1997) Botulinum A toxin therapy: neutralizing and nonneutralizing antibodies\u2014therapeutic consequences. Exp Neurol 147:96\u2013102","journal-title":"Exp Neurol"},{"key":"1911_CR21","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1002\/mds.870110211","volume":"11","author":"PE Greene","year":"1996","unstructured":"Greene PE, Fahn S (1996) Response to botulinum toxin F in seronegative botulinum toxin A-resistant patients. Mov Disord 11:181\u2013184","journal-title":"Mov Disord"},{"key":"1911_CR22","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1136\/jnnp.64.5.577","volume":"64","author":"MK Houser","year":"1998","unstructured":"Houser MK, Sheean GL, Lees AJ (1998) Further studies using higher doses of botulinum toxin type F for torticollis resistant to botulinum toxin type A. J Neurol Neurosurg Psychiatry 64:577\u2013580","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"1911_CR23","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1136\/jnnp.65.6.924","volume":"65","author":"M Naumann","year":"1998","unstructured":"Naumann M, Toyka KV, Mansouri Taleghani B, Ahmadpour J, Reiners K, Bigalke H (1998) Depletion of neutralising antibodies resensitises a secondary non-responder to botulinum A neurotoxin. J Neurol Neurosurg Psychiatry 65:924\u2013927","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"1911_CR24","volume-title":"Manual of botulinum toxin therapy","author":"D Truong","year":"2013","unstructured":"Truong D, Dressler D, Hallett M, Zachary C (2013) Manual of botulinum toxin therapy, 2nd\u00a0edn. Cambridge University Press, Cambridge","edition":"2"}],"container-title":["Journal of Neural Transmission"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00702-018-1911-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00702-018-1911-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00702-018-1911-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,7,30]],"date-time":"2019-07-30T23:20:36Z","timestamp":1564528836000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00702-018-1911-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,7,31]]},"references-count":24,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2018,10]]}},"alternative-id":["1911"],"URL":"https:\/\/doi.org\/10.1007\/s00702-018-1911-3","relation":{},"ISSN":["0300-9564","1435-1463"],"issn-type":[{"value":"0300-9564","type":"print"},{"value":"1435-1463","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,7,31]]},"assertion":[{"value":"26 April 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 July 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 July 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"DD received honoraria for services provided to Allergan, Ipsen, Merz, Lanzhou Institute of Biological Products, Medy-Tox, Revance, Desitin, Syntaxin, Abbvie, Medtronic, St Jude, Boston Scientific, Almirall, Bayer, Sun, Teva, UCB, IAB-Interdisciplinary Working Group for Movement Disorders. He is shareholder of Allergan and holds patents on botulinum toxin and botulinum toxin therapy. LP has nothing to declare. FAS received reimbursement from Abbot, Abbvie, Almirall, Allergan, Bayer, Desitin, Dynamed, Hempel GesundheitsPartner, Ipsen, Johnson & Johnson, Licher, Meda, Medtronic, Merz, Orion, PTZ Nawrath, Sensomotorik & Rehabilitation Hellmuth & Thiel, Sintetica, Sporlastic, Sun, Teva, Tricumed, TRS Med, UCB.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}